it had nothing to do with the news. I think that most have no idea what drugs ACR currently has marketed or in review. If the chart says buy, they buy, says sell, the dump. The whole process is driven by volume and momentum. ACR are on their way to a much better future. Hopefully our partners get quicker results with the FDA. The up side is once developed a generic drug can last decades in production.
Ann: Acrux's fourth generic dossier accepted by FDA for review, page-7
Add to My Watchlist
What is My Watchlist?
